Whalesbook
Pharma Innovation Shifts Gears
Indian drugmakers, long dominant in the generics market, are demonstrating that their strategic bets on innovation are now yielding substantial commercial returns. The year 2025 marked a critical transition, moving drug innovation from research pipelines directly onto company balance sheets, according to industry analysts.
Glenmark Pharmaceuticals secured one of the largest out-licensing deals for an Indian drug firm, agreeing to a $700 million pact with AbbVie Inc. for an under-development cancer drug. Glenn Saldanha, Glenmark's MD and CEO, highlighted the company's resilience in innovation efforts as the key to this success. This achievement signifies a broader industry trend where companies prioritizing novel drug discovery are beginning to reap rewards after facing investor skepticism.
Key Players Showcase Success
Wockhardt Ltd. exemplifies this shift with its two-decade-long commitment to antibiotic research. In 2025, the company launched its antibiotic Miqnaf in India. More significantly, its new chemical entity Zaynich received acceptance for its New Drug Application by the U.S. Food and Drug Administration (FDA), targeting multi-drug resistant infections with an estimated $7 billion market potential. Chairman Habil Khorakiwala noted this culmination of 27-28 years of research places India in the global spotlight, with further U.S. regulatory approval anticipated by mid-2026.
Sun Pharmaceutical Industries reported that its innovative drug sales surpassed generics in the U.S. for the first time in Q2 FY26. Biocon Ltd.'s unit, Biocon Biologics, also expanded market access for its biosimilars, including achieving 'interchangeable' status for insulin aspart from the US FDA. This progress is bolstered by new U.S. FDA draft guidance that could significantly alter biosimilar development economics by potentially waiving Phase III trials under specific conditions.
Policy Support and Future Outlook
Government initiatives, such as the Promotion of Research and Innovation in Pharma MedTech sector (Prip) scheme and the ₹1 trillion Research, Development, and Innovation (RDI) scheme launched in 2025, aim to further catalyze private sector R&D. These policies, coupled with a growing recognition that patient capital in innovation can deliver, are setting the stage for further breakthroughs.
However, achieving China's level of biotech innovation, which is projected to account for 35% of U.S. FDA approvals by 2040, requires parallel advancements in regulatory frameworks. Industry leaders emphasize the need for regulatory predictability and alignment with global standards to attract sustained international investment and reduce structural friction in the innovation ecosystem.